Exact Sciences Corp. (EXAS): Price and Financial Metrics

Exact Sciences Corp. (EXAS): $69.53

3.42 (-4.69%)

POWR Rating

Component Grades








EXAS Price/Volume Stats

Current price $69.53 52-week high $100.77
Prev. close $72.95 52-week low $29.27
Day low $69.26 Volume 2,204,900
Day high $72.56 Avg. volume 1,928,067
50-day MA $85.69 Dividend yield N/A
200-day MA $73.39 Market Cap 12.56B

EXAS Stock Price Chart Interactive Chart >


  • EXAS scores best on the Growth dimension, with a Growth rank ahead of 94.95% of US stocks.
  • EXAS's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • EXAS's current lowest rank is in the Momentum metric (where it is better than 5.46% of US stocks).

EXAS Stock Summary

  • With a market capitalization of $13,604,099,123, EXACT SCIENCES CORP has a greater market value than 87.07% of US stocks.
  • The price/operating cash flow metric for EXACT SCIENCES CORP is higher than 98.61% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 5.91, EXACT SCIENCES CORP has a higher such ratio than 83.05% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EXACT SCIENCES CORP are STAA, ROVR, VERX, VCYT, and TECH.
  • EXAS's SEC filings can be seen here. And to visit EXACT SCIENCES CORP's official web site, go to www.exactsciences.com.

EXAS Valuation Summary

  • EXAS's price/earnings ratio is -31.5; this is 215.6% lower than that of the median Healthcare stock.
  • EXAS's price/sales ratio has moved down 168.1 over the prior 243 months.

Below are key valuation metrics over time for EXAS.

Stock Date P/S P/B P/E EV/EBIT
EXAS 2023-09-18 5.9 4.5 -31.5 -37.1
EXAS 2023-09-15 6.0 4.5 -32.1 -37.7
EXAS 2023-09-14 6.1 4.6 -32.4 -38.0
EXAS 2023-09-13 6.2 4.6 -32.8 -38.4
EXAS 2023-09-12 6.2 4.6 -32.9 -38.5
EXAS 2023-09-11 6.3 4.7 -33.4 -39.0

EXAS Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -119.8%.
  • Its 3 year revenue growth rate is now at 251.87%.
  • The 5 year cash and equivalents growth rate now stands at 1688.13%.
EXAS's revenue has moved up $1,951,375,000 over the prior 70 months.

The table below shows EXAS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 2,084.279 -223.559 -623.506
2022-09-30 2,005.096 -300.168 -716.372
2022-06-30 1,938.402 -300.016 -734.549
2022-03-31 1,851.581 -198.763 -745.398
2021-12-31 1,767.087 -102.236 -595.625
2021-09-30 1,759.614 33.74 -811.824

EXAS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXAS has a Quality Grade of D, ranking ahead of 24.25% of graded US stocks.
  • EXAS's asset turnover comes in at 0.281 -- ranking 445th of 561 Business Services stocks.
  • ISGN, ADBE, and FTAI are the stocks whose asset turnover ratios are most correlated with EXAS.

The table below shows EXAS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.281 0.750 -0.310
2021-06-30 0.301 0.755 -0.344
2021-03-31 0.302 0.752 -0.332
2020-12-31 0.328 0.762 -0.274
2020-09-30 0.315 0.755 -0.171
2020-06-30 0.319 0.751 -0.126

EXAS Price Target

For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $148.88 Average Broker Recommendation 1.28 (Strong Buy)

Exact Sciences Corp. (EXAS) Company Bio

Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer. (Source:Wikipedia)

EXAS Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream

Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.

Yahoo | September 12, 2023

Where Will Exact Sciences Be in 5 Years?

Over the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known for its at-home, noninvasive colorectal cancer screening option, Cologuard.

Yahoo | September 9, 2023

Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs

Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.

Yahoo | September 7, 2023

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.

Yahoo | September 7, 2023

The 3 Best Cathie Wood Stocks to Buy Now: September 2023

Most of Cathie Wood's stock picks are not too impressive.

Larry Ramer on InvestorPlace | September 6, 2023

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo -17.80%
3-mo -24.93%
6-mo 4.90%
1-year 102.42%
3-year -4.65%
5-year -8.85%
YTD 40.44%
2022 -36.39%
2021 -41.26%
2020 43.26%
2019 46.56%
2018 20.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!